Grifols, S.A. (NASDAQ:GRFS) Sees Significant Drop in Short Interest

Grifols, S.A. (NASDAQ:GRFS) was the target of a significant decline in short interest in September. As of September 30th, there was short interest totalling 4,570,000 shares, a decline of 9.7% from the September 15th total of 5,060,000 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average daily volume of 1,470,000 shares, the days-to-cover ratio is currently 3.1 days.

Grifols Stock Down 0.2 %

GRFS traded down $0.02 during trading hours on Wednesday, hitting $8.49. 456,025 shares of the company’s stock were exchanged, compared to its average volume of 1,988,275. The stock has a market cap of $5.84 billion, a price-to-earnings ratio of 8.32 and a beta of 0.50. Grifols has a 1-year low of $5.30 and a 1-year high of $12.15. The stock’s 50-day moving average is $8.52 and its two-hundred day moving average is $7.65. The company has a quick ratio of 0.80, a current ratio of 1.68 and a debt-to-equity ratio of 1.06.

Grifols (NASDAQ:GRFS) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion during the quarter. Sell-side analysts predict that Grifols will post 0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GRFS. Hennion & Walsh Asset Management Inc. increased its holdings in Grifols by 28.0% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 325,996 shares of the biotechnology company’s stock worth $2,178,000 after buying an additional 71,387 shares during the last quarter. Cohen Investment Advisors LLC acquired a new position in shares of Grifols during the 1st quarter worth about $80,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Grifols by 66.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 23,461 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 9,350 shares during the period. Team Hewins LLC lifted its stake in Grifols by 11.8% in the 1st quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 4,324 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in Grifols by 5.3% during the first quarter. Sei Investments Co. now owns 2,109,416 shares of the biotechnology company’s stock worth $14,091,000 after purchasing an additional 107,000 shares during the period.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.